Asia Pacific Multiple Myeloma Therapeutics Market to reach US$2.8 bn over 2015-2021 – APAC Market Focusing 5 classes of drugs being used in this therapy and expected Market growth rate in Australia, China, India and Japan: ResearchMoz

Albany, NY, Dec. 15, 2015 (GLOBE NEWSWIRE) -- The research report is titled “Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments”, and it states that the overall value of the Asia Pacific market for multiple myeloma therapeutics stood at US$1.7 bn in 2014.

According to analysts, the market is projected to expand at a CAGR of 7.40% during the period from 2015 and 2021 and reach a market value of US$2.8 bn by the end of the forecast period.

This report offers a comprehensive analysis of the Asia Pacific multiple myeloma therapeutics market on the basis of drug types, production volume, annual revenue, the cost associated with research and development, and the sales dynamics of blockbuster and major marketed drugs during the period from 2015 to 2021.

The Asia Pacific market for multiple myeloma therapeutics is undergoing a phase of significant development. The growth in this market is primarily driven by the emergence of novel therapies. These novel therapies have enhanced the clinical results across all stages of multiple myeloma. In addition to this, the absence of generic competition in Japan, China, and Australia is likely to propel the multiple myeloma therapeutics market in Asia Pacific over the forecast period, states the report.

Get Sample Research Report:

Velcade, Revlimid, and Thalomid are the leading brands, providing treatment for multiple myeloma in Asia Pacific. Analysts expect Revlimid, and Thalomid to maintain their dominance, owing to the absence of generic completion in the multiple myeloma therapeutics market in Asia Pacific, notes the market study. However, Velcade, the proteasome inhibitor, is likely to face severe challenge as its patent is going to expire in China by the end of 2015, in Japan by 2018, in Australia by 2020. The only consolation for this drug is its market in India, which is showing healthy growth. Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.

Browse full report at:

Some of the new entrants in the Asia Pacific multiple myeloma therapeutics market are Daratumumab and Elotuzumab. Daratumumab has been trialed in combination with dexamethasone and Revlimid, and Elotuzumab has been trialed in combination with Revlimid only. Another drug, Kyprolis, is likely to be introduced in this region over the next few years.

Market experts anticipate these emerging treatments for multiple myeloma to offer alternatives in the refractory or relapsed disease setting, contributing significantly to the growth of this market.

Other prominent pipeline drugs for multiple myeloma are filanesib, Zolinza, and plitidepsin, states the research report.

About Us

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Mr. Nachiket Ghumare State Tower, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-621-2074 USA - Canada Toll Free: 866-997-4948 Website:

Source:Researchmoz Global Pvt Ltd